Samtidig administration af immunmodulatorer er blevet forbundet med en lavere hyppighed af antistoffer overfor infliximab og en reduktion i frekvensen af infusionsreaktioner.
Concomitant administration of immunomodulators has been associated with lower incidence of antibodies to infliximab and a reduction in the frequency of infusion reactions.